Home, About, Contact Us, FAQ

A new molecular target identified in depression may mean more effective treatment, fewer side effects


#1

#2

Thank you for posting @twinklestars !
This may be good news for people with depression.
In schizophrenia Lumateperone seems promising in terms of less side effects.


#3

I read the article @twinklestars , i was hoping it would have a novel neurotransmitter target. But the gist i got was that it would just do the last step of what ssris do rather than the series of chemical steps ssris normally require. So same outcome, i am interested in future antidepressants cuz they may help relieve anhedonia. Some depressed ppl only have that 1 symptom but its one of two core features besides sad mood.

Iti 007 came about similarly. They just studied biomarkers of the current APs and created a drug thats a novel compound but would produce a similar result as Current AP biomarkers. Thats why i am not that excited about it. Just more crap


#4

If you can target the signaling molecule, you could potentially avoid the side effects associated with targeting the neurotransmitter system.

But, this is a decade or more out, probably.

That’s interesting, I didn’t know the drug discovery process for ITI007.


#5

But u dont get a new med, u just get the same crap with less side effects. Negative symptoms are a lot worse than side effects of meds, wish they would focus on that rather than trying to curb obesity. I guess if u have ED and treatable depression this piece of news would make u happy.

Its on the intracellular therapies website. Cuz the guy in managenent of that company was a nobel prize winner for designing a way to track certain biomarkers in brain. He is using this system to found his compounds. Something new, but not the answer most of us are looking for.